These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34003553)

  • 1. Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1.
    Kandasamy P; Zlobec I; Nydegger DT; Pujol-Giménez J; Bhardwaj R; Shirasawa S; Tsunoda T; Hediger MA
    Mol Oncol; 2021 Oct; 15(10):2782-2800. PubMed ID: 34003553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
    Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
    Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
    J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.
    Najumudeen AK; Ceteci F; Fey SK; Hamm G; Steven RT; Hall H; Nikula CJ; Dexter A; Murta T; Race AM; Sumpton D; Vlahov N; Gay DM; Knight JRP; Jackstadt R; Leach JDG; Ridgway RA; Johnson ER; Nixon C; Hedley A; Gilroy K; Clark W; Malla SB; Dunne PD; Rodriguez-Blanco G; Critchlow SE; Mrowinska A; Malviya G; Solovyev D; Brown G; Lewis DY; Mackay GM; Strathdee D; Tardito S; Gottlieb E; ; Takats Z; Barry ST; Goodwin RJA; Bunch J; Bushell M; Campbell AD; Sansom OJ
    Nat Genet; 2021 Jan; 53(1):16-26. PubMed ID: 33414552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
    Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
    Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
    Bröer A; Rahimi F; Bröer S
    J Biol Chem; 2016 Jun; 291(25):13194-205. PubMed ID: 27129276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
    Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ablation of the
    Bröer A; Gauthier-Coles G; Rahimi F; van Geldermalsen M; Dorsch D; Wegener A; Holst J; Bröer S
    J Biol Chem; 2019 Mar; 294(11):4012-4026. PubMed ID: 30635397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
    Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
    Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lobetyolin inhibits the proliferation of breast cancer cells
    Chen Y; Tian Y; Jin G; Cui Z; Guo W; Zhang X; Liu X
    Hum Exp Toxicol; 2021 Dec; 40(12):2074-2086. PubMed ID: 34075790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TEAD1 (TEA Domain Transcription Factor 1) Promotes Smooth Muscle Cell Proliferation Through Upregulating SLC1A5 (Solute Carrier Family 1 Member 5)-Mediated Glutamine Uptake.
    Osman I; He X; Liu J; Dong K; Wen T; Zhang F; Yu L; Hu G; Xin H; Zhang W; Zhou J
    Circ Res; 2019 Apr; 124(9):1309-1322. PubMed ID: 30801233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
    Nachef M; Ali AK; Almutairi SM; Lee SH
    Front Immunol; 2021; 12():624324. PubMed ID: 33953707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNHG14 facilitates cell proliferation in colorectal cancer through targeting KRAS via Hippo-YAP signaling.
    Shen M; Su Y; Song S; Liu D; Liu Z; Chen D; Pan Y; Zhang L; Xu X
    Cell Mol Biol (Noisy-le-grand); 2023 Mar; 69(3):64-68. PubMed ID: 37300688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
    Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
    Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASCT2 is a major contributor to serine uptake in cancer cells.
    Conger KO; Chidley C; Ozgurses ME; Zhao H; Kim Y; Semina SE; Burns P; Rawat V; Lietuvninkas L; Sheldon R; Ben-Sahra I; Frasor J; Sorger PK; DeNicola GM; Coloff JL
    Cell Rep; 2024 Aug; 43(8):114552. PubMed ID: 39068660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells.
    Polet F; Martherus R; Corbet C; Pinto A; Feron O
    Oncotarget; 2016 Jul; 7(29):46371-46383. PubMed ID: 27344174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting glutamine transport to suppress melanoma cell growth.
    Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
    Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.